Bioelectronic medicine maker Tivic Health's Q3 net loss widens

Valion Bio

14/11/2025 21:39

Overview

Tivic Health Q3 revenue rises to $146,000, final quarter for direct ClearUP sales

Net loss widens to $2.6 mln in Q3, impacted by consumer business wind down

Outlook

Company did not provide specific financial guidance for future quarters or years

Result Drivers

MILITARY INTEREST - Tivic advanced discussions on deploying Entolimod as a military countermeasure at MHSRS

Operating expenses totaled $2.3 million, compared with $1.5 million for the same period in 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$146,000
Q3 Net Income
-$2.60 mln
Q3 Basic EPS
-$1.97
Q3 Gross Profit
-$145,000
Q3 Operating Expenses
$2.34 mln
Q3 Operating Income
-$2.48 mln


Press Release: ID:nACSKJPQDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)